Ocugen Provides Business Update and Second Quarter 2020 Financial Results
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) reported second quarter 2020 financial results along with a general business update.
Read MoreGene delivery
Ocugen Receives Fourth FDA Orphan Drug Designation for the Same Product, OCU400 (AAV-NR2E3) Gene Therapy
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, announced the U.S. Food and Drug Administration (FDA) …
Read More Ocugen Granted FDA Orphan Drug Designation for OCU400 (AAV-hNR2E3) Gene Therapy
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, announced the U.S. Food and Drug Administration (FDA) …
Read More Ocugen to Discontinue Phase 3 oGVHD Trial
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat the whole eye, today announced the decision to discontinue the …
Read More
Nature Gene Therapy Publishes Preclinical Data of Ocugen’s OCU400 (NR2E3-AAV) Genetic Modifier to treat Retinitis Pigmentosa (RP)
MALVERN, PA — Ocugen, Inc., (NASDAQ: OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat rare and underserved ophthalmic diseases, announced the publication in Nature Gene Therapy …
Read More